Tenofovir Alafenamide prior authorization at Horizon Blue Cross Blue Shield of New Jersey
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
Horizon Blue Cross Blue Shield of New Jersey reviews Tenofovir Alafenamide prior authorizations against its medical policy . Horizon Blue Cross Blue Shield of New Jersey-specific context: Only BCBS licensee in New Jersey; ~3.7M members. OMNIA Health Plans (tiered network) generate frequent appeals — tier-2 hospital usage carries higher cost share. NJ DOBI oversight; NJ has a strong external review program (IHCAP via Maximus).
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Horizon Blue Cross Blue Shield of New Jersey's medical policy URL referenced in the cover letter
Horizon Blue Cross Blue Shield of New Jersey's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- OMNIA tier-1 vs tier-2 provider disputes
- Step therapy on biologics
- Behavioral health prior auth
- Out-of-state emergency reductions
If the PA is denied
Horizon Blue Cross Blue Shield of New Jersey gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.horizonblue.com/providers) with the same packet plus a peer-reviewed citation supporting Tenofovir Alafenamidefor the patient's indication.
Contact Horizon Blue Cross Blue Shield of New Jersey
- Provider portal: https://www.horizonblue.com/providers
Frequently asked questions
What documentation does Horizon Blue Cross Blue Shield of New Jersey need for Tenofovir Alafenamide prior auth?
Horizon Blue Cross Blue Shield of New Jersey's typical PA packet for Tenofovir Alafenamide: (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Horizon Blue Cross Blue Shield of New Jersey?
Standard Tenofovir Alafenamide PA decisions at Horizon Blue Cross Blue Shield of New Jersey: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Horizon Blue Cross Blue Shield of New Jersey most often reject Tenofovir Alafenamide for?
Across Horizon Blue Cross Blue Shield of New Jersey's book the common rejection patterns include: OMNIA tier-1 vs tier-2 provider disputes; Step therapy on biologics; Behavioral health prior auth. For Tenofovir Alafenamide specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Horizon Blue Cross Blue Shield of New Jersey on Tenofovir Alafenamide?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the Tenofovir Alafenamide PA packet
Open ApprovalHelp — generate a Tenofovir Alafenamide prior-auth packet tailored to Horizon Blue Cross Blue Shield of New Jersey's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com